Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Amplification”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Not applicableUnknownNCT02002416
What this trial is testing

Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma

Who this might be right for
Gastric Cancer
Sun Yat-sen University 200
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Testing effectiveness (Phase 2)Study completedNCT02449551
What this trial is testing

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357975
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 50
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03539536
What this trial is testing

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AbbVie 270
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)UnknownNCT04338243
What this trial is testing

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Who this might be right for
Negative T790M Mutation and Met Amplification
Haihe Biopharma Co., Ltd. 70
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Looking for participantsNCT06116682
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network 88
Testing effectiveness (Phase 2)Looking for participantsNCT06947291
What this trial is testing

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Who this might be right for
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 350
Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06452433
What this trial is testing

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 91
Load More Results